72 results
8-K
RVPH
Reviva Pharmaceuticals Holdings Inc.
15 Apr 24
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
5:01pm
Phase 3 studies showing efficacy at week 4 that were to be accompanied by long-term safety data of at least 12 months, this could be supportive of an NDA … submission for the acute treatment of schizophrenia. In addition, the FDA indicated that it will require a long-term randomized withdrawal study post
8-K
EX-99.1
RVPH
Reviva Pharmaceuticals Holdings Inc.
15 Apr 24
Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia
5:01pm
registrational Phase 3 RECOVER-2 study -
- Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application … (NDA) for brilaroxazine in schizophrenia –
- Topline data from 1-year open-label extension (OLE) long-term safety trial expected in Q4 2024
8-K
EX-99.1
RVPH
Reviva Pharmaceuticals Holdings Inc.
15 Apr 24
Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights
8:20am
will inform on the long-term safety and efficacy of brilaroxazine. With these important trials advancing and most non-clinical activities complete, we … and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s 1-year open label extension (OLE) trial evaluating the long
424B4
RVPH
Reviva Pharmaceuticals Holdings Inc.
13 Feb 24
Prospectus supplement with pricing info
5:00pm
positive Phase 2 REFRESH and Phase 3 RECOVER trials, as well as an ongoing 1-year open label extension (OLE) trial evaluating the long-term safety
424B5
65q4vija3vl g4je25r
17 Nov 23
Prospectus supplement for primary offering
4:03pm
8-K
EX-99.1
zc0lqjxcexixhre
14 Nov 23
Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights
4:12pm
8-K
EX-99.1
sunopx58me10
30 Oct 23
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
8:20am
8-K
mgt2b jeoxy9mf
30 Oct 23
Reviva Announces Positive Topline Results from Global Pivotal Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia
8:20am
8-K
EX-99.1
k9sz4j0la9 xqefvtus
17 Aug 23
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
6:30am
8-K
6vndzan
17 Aug 23
Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia
6:30am
8-K
khu76sl4
23 Jun 23
Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
6:30am
8-K
EX-99.1
rzv mofhkz53drp1ru
23 Jun 23
Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
6:30am
8-K
EX-99.1
cy2ue2rdec5i gs
30 Mar 23
Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights
7:46am
424B4
iyvka2
18 Oct 22
Prospectus supplement with pricing info
7:01am